Anti-Inflammatory & Cancer Immunomodulation Intelligence: Clinical Progress, FPR-Pathway Mechanisms, and High-Purity Reagents for Resolution Pharmacology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Annexin A1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANXA1 Full-Length Recombinant Protein (HEK293 expressed, >95% purity, endotoxin <1EU/µg, calcium-dependent conformation, sequence verified) | View ANXA1 Products |
| N-Terminal Peptide | ANXA1 Ac2-26 (Active Peptide, synthetic N-terminal domain for FPR2/ALX binding assays, HPLC >95%) | View ANXA1 Products |
| Gene Delivery | ANXA1 Premade Lentivirus Particles (CMV/EF1a promoter, Puro/Neo selection, for stable overexpression) | View ANXA1 Products |
| RNAi Validator | ANXA1 siRNA Set (3 unique targets, for knockdown verification in functional assays) | View ANXA1 Products |
| Benchmark Antibody | Anti-ANXA1 Recombinant Monoclonal Reference (sequence-defined positive control for detection and immunoprecipitation) | View ANXA1 Products |
| Primary Receptor | FPR2/ALX (GPCR target for pro-resolving pathways, required for ANXA1 mimetic screening) | View FPR2 Products |
| Secondary Receptor | FPR1 (counter-screening target to assess receptor selectivity of ANXA1-derived peptides) | View FPR1 Products |
| Tertiary Receptor | FPR3 (extended off-target panel for comprehensive selectivity profiling) | View FPR3 Products |
| Related Target | ANXA2 (highly homologous annexin family member, essential for counter-screening and specificity assays) | View ANXA2 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-Dependent Conformational Integrity | HEK293 Expressed ANXA1 with Native Calcium-Binding Sites. Theoretical MW 38.7 kDa confirmed by Mass Spec. |
| FPR2 vs FPR1 Selectivity Profiling | Human/Mouse/Cyno Ortholog Receptor Panel (FPR1, FPR2, FPR3) available with >95% purity for cross-species evaluation. |
| N-Terminal Epitope Accessibility | Full-length ANXA1 and Ac2-26 Peptide (aa 2-26) available. Both Endotoxin Controlled (<1EU/µg). |
| False Positives in Migration Assays | Validated ANXA1 siRNA included for specificity controls in neutrophil chemotaxis assays. |
| Subfamily Counter-Screening (ANXA2/ANXA5) | Homolog panel proteins strictly verified by mass spectrometry and sequence alignment for off-target liability. |
| Cross-Species Evaluation (Cyno/Mouse) | Human/Mouse/Cyno ANXA1 ortholog proteins available with >95% purity, sequence verified. |
| Endotoxin Interference in Immune Assays | All proteins endotoxin controlled (<1 EU/µg), critical for innate immune and macrophage activation studies. |
Live ANXA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The Annexin A1 therapeutic landscape is transitioning from biomarker discovery to targeted intervention, with particular momentum in pro-resolving therapy for inflammatory diseases and tumor microenvironment (TME) modulation. As the understanding of ANXA1's dual role—intracellular scaffold versus extracellular FPR2 agonist—matures, R&D focus has shifted toward N-terminal peptide mimetics (Ac2-26) and neutralizing antibodies that block the ANXA1/FPR2 axis in cancer contexts. The next wave of development targets context-dependent agonism: leveraging ANXA1 for anti-inflammatory resolution in COPD and ARDS while inhibiting the same pathway in metastatic cancers where ANXA1 promotes tumor cell migration. Major players are shifting from broad immunosuppression to highly selective TME modulation without disrupting systemic immune homeostasis. As first-generation glucocorticoid-sparing peptide mimetics enter early-phase studies, the next wave includes targeted monoclonal antibodies, bi-specifics, and targeted protein degraders for refractory cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Mimetics | Academic Consortia, Resolving Pharma | ARDS, COPD, SLE, RA | FPR2/ALX Binding (Need Calcium-Intact ANXA1 and Ac2-26 for comparative studies) |
| Monoclonal Antibodies (Neutralizing) | Oncology Biotechs | Metastatic Breast, Pancreatic Cancer | N-Terminal Epitope Mapping (Need Full-length vs Ac2-26 proteins; selectivity vs ANXA2/ANXA5) |
| Small Molecule (FPR2 Agonist / PPI Disruptor) | Inflammation Focused Cos, Discovery-stage Pharma | Neutrophil-mediated inflammation, Inflammatory Cancer | Selectivity Assay (Need FPR1/FPR2/FPR3 panel; ANXA1-FPR2 co-assay reagents) |
| Targeted Protein Degraders (PROTACs) | Preclinical Innovators | Refractory Cancers | Degradation Assays (Need specific anti-ANXA1 for Western Blot/Intracellular tracking) |
| Gene Therapy (Overexpression) | Gene Therapy Startups | Severe Inflammation | Functional Validation (Need Lentivirus for stable ANXA1 expression) |
Associated Target Recommendations
Based on ANXA1's FPR signaling axis and inflammatory network, the following cross-sell targets are strongly recommended for a comprehensive drug discovery program:
- FPR2/ALX (Formyl Peptide Receptor 2): Primary functional receptor for ANXA1. Clients developing FPR2 small molecule agonists or ANXA1 peptide mimetics should use FPR2 recombinant ECD protein and stable cell lines for ligand competition assays.
- FPR1: Essential off-target control for selectivity profiling; pro-inflammatory receptor that must be used as negative counter-screen.
- ANXA2 (Annexin A2): Crucial for subfamily counter-screening to avoid cross-reactivity in antibody-based modalities.
- CXCR4/CXCL12: ANXA1-FPR2 axis synergizes with CXCL12-CXCR4 in tumor cell migration; co-targeting is an emerging anti-metastatic strategy.
- SerpinA1 (Alpha-1 Antitrypsin): Glucocorticoid-induced anti-inflammatory protein, synergistic with ANXA1 in COPD/ARDS models; potential for combination therapy.